Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Gilead Sciences, Inc. : FDA Panel Backs Gilead's HIV 'Quad' Medicine

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/11/2012 | 09:06pm CEST
   By Jennifer Corbett Dooren 
   Of  
 

A federal advisory panel Friday backed an experimental Gilead Sciences Inc. (GILD) HIV medicine known as the Quad.

The company is seeking approval from the Food and Drug Administration to market the product, which combines four active ingredients into one pill, meant to be taken once daily.

The medicine was reviewed on Friday by the agency's antiviral drugs advisory panel, which is made up of non-FDA medical experts. The panel voted 13 to 1 on a question that asked if the submitted clinical data supported approval of the drug. The panel vote amounts to a recommendation that the FDA approve the drug. The agency usually follows panel recommendations but isn't required to. The FDA is expected to make a decision by the end of August.

Quad is a combination of four active ingredients in one pill. It combines Gilead's double-drug Truvada, the drug elvitegravir and an agent that boosts blood levels of certain HIV drugs, cobicistat.

Gilead is hoping that the one-pill, once-daily Quad regimen will provide more convenience to HIV patients, many of whom now take multiple pills for treatment. Some analysts think it could become a blockbuster seller.

-By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; jennifer.corbett@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
08/18 NEW SENIOR INVESTMENT : Gilead Sciences (GILD) Shareholder Underhill Investment ..
08/17 GILEAD SCIENCES : Announces U.S. FDA Priority Review Designation for Fixed-Dose ..
08/17 GILEAD SCIENCES : Receives Approval in Canada for VOSEVI™ (Sofosbuvir/Velp..
08/16 GILEAD SCIENCES : `s Newer Tenofovir Patents Might Aid Its HIV Franchise
08/16 GILEAD SCIENCES : to unveil 23-acre campus in La Verne this week
08/15 GILEAD SCIENCES : Announces U.S. FDA Priority Review Designation for Fixed Dose ..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/10 GILEAD SCIENCES : Announces U.S. FDA Priority Review Designation for Fixed-Dose ..
More news
News from SeekingAlpha
08/20 Pricing In A Lot Of Bad Luck
08/18 Hundred Thousand Dollars Income Portfolio - The Market Is Simply Overpriced
08/18 GILEAD : Road To $100
08/16 Very Cautious On AbbVie's Fundamentals
08/16 Half Million Dollar Income Portfolio - Keep Living The Dream
Financials ($)
Sales 2017 25 839 M
EBIT 2017 16 155 M
Net income 2017 10 609 M
Debt 2017 8 861 M
Yield 2017 2,94%
P/E ratio 2017 9,09
P/E ratio 2018 10,29
EV / Sales 2017 3,99x
EV / Sales 2018 4,33x
Capitalization 94 170 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 80,1 $
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES0.70%94 170
AMGEN14.42%122 067
CELGENE CORPORATION10.28%99 867
REGENERON PHARMACEUTICALS27.48%50 145
VERTEX PHARMACEUTICALS101.07%37 346
ACTELION22.00%30 302